Recent News Releases

King of Prussia, Pa. 09 Jan 2020 Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...

Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of...

KING OF PRUSSIA, Pa.– December 9, 2019 – Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine...

Sydney, Australia 04 Dec 2019 CSL Limited (ASX:CSL; USOTC:CSLLY) is steadily advancing its Research & Development (R&D) pipeline and capabilities to deliver a highly differentiated product...

For a fifth consecutive year, Iron Deficiency Day aims to inform about the impact and symptoms of iron deficiency Iron Deficiency Day 2019 encourages people to ‘take iron seriously’ Supported...

Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity...

St Gallen, 18 November 2019 – Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020. Lee Heeson...

KING OF PRUSSIA, Pa. – 23 October 2019 – Harvard Business Review (HBR) today named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for...

CSL statement in response to media reports on case against Joseph Chiao The Sydney Morning Herald on 18 October 2019 reported that former CSL employee Dr Joseph Chiao ‘stole patient data’. CSL...

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and...

MADRID, Spain – 27 September 2019 – Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the

The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative...

New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit. 23 Sep 2019 Seqirus, a global leader in influenza prevention, has...

This news release is intended for Health Professional media only. 17 Sep 2019 Seqirus, a global leader in influenza prevention, and Laboratoire Arrow, a fast growing player in the pharmaceutical...

St Gallen, 11 September 2019 – Vifor Pharma today announced changes to its management. Dr Klaus Henning Jensen will join the company as Chief Medical Officer and Member of the Executive...

St Gallen, 9 September 2019 – Vifor Pharma announced today that Standard & Poor's (S&P) assigned a BBBcredit rating with stable outlook to Vifor Pharma. This inaugural investment grade credit...

This news release is intended for Health Professional media only. Maidenhead, 5 September 2019 Seqirus, a global leader in influenza prevention, announced today that it has started on-time...

Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc....

Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating...

Summit, NJ – August 30, 2019 Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from clinical...

Seqirus announced it will feature data in 3 presentations and 24 posters on the company’s adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of...

Strong financial performance in H1 2019 Continued positive performance of all three strategic growth drivers Guidance raised on 2019 net sales and EBITDA On track to achieve Milestone 2020 ZURICH,...